Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.

@article{Rijckborst2010EarlyOP,
  title={Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.},
  author={Vincent Rijckborst and Bettina E Hansen and Yilmaz Çakaloğlu and P Ferenci and Fehmi Tabak and M Volkan Akdoğan and Krzysztof Adam Simon and Ulus Salih Akarca and R Flisiak and E. R. Verhey and Anneke J. van Vuuren and Charles A. B. Boucher and Martijn J ter Borg and Harry L. A. Janssen},
  journal={Hepatology},
  year={2010},
  volume={52 2},
  pages={454-61}
}
UNLABELLED Peginterferon alfa-2a results in a sustained response (SR) in a minority of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). This study investigated the role of early on-treatment serum hepatitis B surface antigen (HBsAg) levels in the prediction of SR in HBeAg-negative patients receiving peginterferon alfa-2a. HBsAg (Architect from Abbott) was quantified at the baseline and during treatment (weeks 4, 8, 12, 24, 36, and 48) and follow-up (weeks 60 and… CONTINUE READING